16 results
PRE 14A
AQST
Aquestive Therapeutics Inc
18 Apr 23
Preliminary proxy
8:50am
novel sensors, initially at the Air Force Research Laboratory and subsequently in the private sector. Dr. Wargacki received his B.S. in Chemistry from
8-K
EX-99.1
AQST
Aquestive Therapeutics Inc
1 Nov 22
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:21pm
. Epinephrine is known to degrade quickly and, as the EpiPen label currently indicates, “[e]pinephrine solution deteriorates rapidly on exposure to air … or light.” AQST-109 has been designed to minimize exposure to air and light until opened for use. The FDA’s written response indicates that Aquestive’s
8-K
EX-99.1
AQST
Aquestive Therapeutics Inc
11 Oct 22
Other Events
8:35am
]pinephrine solution deteriorates rapidly on exposure to air or light.” AQST-109 has been designed to minimize exposure to air and light until opened
8-K
EX-1.1
p8hmazvau
8 Jun 22
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
4:22pm
8-K
EX-10.1
wyqn31mnqu o1
8 Jun 22
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
4:22pm
DRS/A
EX-4.2
b46dtm c311e
22 May 18
Draft registration statement (amended)
12:00am
S-1
5wewaloqs1x
14 May 07
IPO registration
12:00am
- Prev
- 1
- Next